TY - JOUR AU - Schwedt, T. J. PY - 2014 DA - 2014// TI - Chronic migraine JO - BMJ (Clinical research ed) VL - 348 ID - Schwedt2014 ER - TY - JOUR PY - 2018 DA - 2018// TI - The international classification of headache disorders, 3rd edition JO - Cephalalgia VL - 38 ID - ref2 ER - TY - JOUR AU - Natoli, J. L. AU - Manack, A. AU - Dean, B. AU - Butler, Q. AU - Turkel, C. C. AU - Stovner, L. PY - 2010 DA - 2010// TI - Global prevalence of chronic migraine: a systematic review JO - Cephalalgia VL - 30 UR - https://doi.org/10.1111/j.1468-2982.2009.01941.x DO - 10.1111/j.1468-2982.2009.01941.x ID - Natoli2010 ER - TY - JOUR AU - Stewart, W. F. AU - Wood, G. C. AU - Manack, A. AU - Varon, S. F. AU - Buse, D. C. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - Employment and work impact of chronic migraine and episodic migraine JO - J Occup Environ Med VL - 52 UR - https://doi.org/10.1097/JOM.0b013e3181c1dc56 DO - 10.1097/JOM.0b013e3181c1dc56 ID - Stewart2010 ER - TY - JOUR AU - Lanteri-Minet, M. AU - Duru, G. AU - Mudge, M. AU - Cottrell, S. PY - 2011 DA - 2011// TI - Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review JO - Cephalalgia VL - 31 UR - https://doi.org/10.1177/0333102411398400 DO - 10.1177/0333102411398400 ID - Lanteri-Minet2011 ER - TY - JOUR AU - Blumenfeld, A. M. AU - Varon, S. F. AU - Wilcox, T. K. AU - Buse, D. C. AU - Kawata, A. K. AU - Manack, A. PY - 2011 DA - 2011// TI - Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS) JO - Cephalalgia VL - 31 UR - https://doi.org/10.1177/0333102410381145 DO - 10.1177/0333102410381145 ID - Blumenfeld2011 ER - TY - JOUR AU - Buse, D. C. AU - Scher, A. I. AU - Dodick, D. W. AU - Reed, M. L. AU - Fanning, K. M. AU - Manack Adams, A. PY - 2016 DA - 2016// TI - Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study JO - Mayo Clin Proc VL - 91 UR - https://doi.org/10.1016/j.mayocp.2016.02.013 DO - 10.1016/j.mayocp.2016.02.013 ID - Buse2016 ER - TY - JOUR AU - Bigal, M. E. AU - Serrano, D. AU - Reed, M. AU - Lipton, R. B. PY - 2008 DA - 2008// TI - Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment JO - Neurology VL - 71 UR - https://doi.org/10.1212/01.wnl.0000323925.29520.e7 DO - 10.1212/01.wnl.0000323925.29520.e7 ID - Bigal2008 ER - TY - JOUR AU - Bloudek, L. M. AU - Stokes, M. AU - Buse, D. C. AU - Wilcox, T. K. AU - Lipton, R. B. AU - Goadsby, P. J. PY - 2012 DA - 2012// TI - Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS) JO - J Headache Pain VL - 13 UR - https://doi.org/10.1007/s10194-012-0460-7 DO - 10.1007/s10194-012-0460-7 ID - Bloudek2012 ER - TY - JOUR AU - Dodick, D. W. AU - Loder, E. W. AU - Manack Adams, A. AU - Buse, D. C. AU - Fanning, K. M. AU - Reed, M. L. PY - 2016 DA - 2016// TI - Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study JO - Headache VL - 56 UR - https://doi.org/10.1111/head.12774 DO - 10.1111/head.12774 ID - Dodick2016 ER - TY - STD TI - World Health Organization. Headache disorders fact sheet (2016) [Available from: http://www.who.int/mediacentre/factsheets/fs277/en/] UR - http://www.who.int/mediacentre/factsheets/fs277/en/ ID - ref11 ER - TY - JOUR AU - Starling, A. J. AU - Dodick, D. W. PY - 2015 DA - 2015// TI - Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care JO - Mayo Clin Proc VL - 90 UR - https://doi.org/10.1016/j.mayocp.2015.01.010 DO - 10.1016/j.mayocp.2015.01.010 ID - Starling2015 ER - TY - JOUR AU - Blumenfeld, A. M. AU - Aurora, S. K. AU - Laranjo, K. AU - Papapetropoulos, S. PY - 2015 DA - 2015// TI - Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine JO - BMC Neurol VL - 15 UR - https://doi.org/10.1186/s12883-015-0353-x DO - 10.1186/s12883-015-0353-x ID - Blumenfeld2015 ER - TY - JOUR AU - Stovner, L. J. AU - Linde, M. AU - Gravdahl, G. B. AU - Tronvik, E. AU - Aamodt, A. H. AU - Sand, T. PY - 2014 DA - 2014// TI - A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study JO - Cephalalgia VL - 34 UR - https://doi.org/10.1177/0333102413515348 DO - 10.1177/0333102413515348 ID - Stovner2014 ER - TY - JOUR AU - Davies, B. AU - Gaul, C. AU - Martelletti, P. AU - Garcia-Monco, J. C. AU - Brown, S. PY - 2017 DA - 2017// TI - Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data JO - J Headache Pain VL - 18 UR - https://doi.org/10.1186/s10194-017-0802-6 DO - 10.1186/s10194-017-0802-6 ID - Davies2017 ER - TY - STD TI - Topamax. Buckinghamshire, UK: Janssen-Cilag Limited; 2017 ID - ref16 ER - TY - STD TI - Topamax. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017 ID - ref17 ER - TY - JOUR AU - Diener, H. C. AU - Bussone, G. AU - Oene, J. C. AU - Lahaye, M. AU - Schwalen, S. AU - Goadsby, P. J. PY - 2007 DA - 2007// TI - Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study JO - Cephalalgia VL - 27 UR - https://doi.org/10.1111/j.1468-2982.2007.01326.x DO - 10.1111/j.1468-2982.2007.01326.x ID - Diener2007 ER - TY - STD TI - Botox. Westport, County Mayo, Ireland: Allergan Pharmaceuticals Ireland; 2014 ID - ref19 ER - TY - JOUR AU - Diener, H. C. AU - Dodick, D. W. AU - Aurora, S. K. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial JO - Cephalalgia VL - 30 UR - https://doi.org/10.1177/0333102410364677 DO - 10.1177/0333102410364677 ID - Diener2010 ER - TY - JOUR AU - Aurora, S. K. AU - Dodick, D. W. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Silberstein, S. D. AU - Lipton, R. B. PY - 2010 DA - 2010// TI - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial JO - Cephalalgia VL - 30 UR - https://doi.org/10.1177/0333102410364676 DO - 10.1177/0333102410364676 ID - Aurora2010 ER - TY - JOUR AU - Aurora, S. K. AU - Winner, P. AU - Freeman, M. C. AU - Spierings, E. L. AU - Heiring, J. O. AU - DeGryse, R. E. PY - 2011 DA - 2011// TI - OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program JO - Headache VL - 51 UR - https://doi.org/10.1111/j.1526-4610.2011.01990.x DO - 10.1111/j.1526-4610.2011.01990.x ID - Aurora2011 ER - TY - JOUR AU - Blumenfeld, A. AU - Silberstein, S. D. AU - Dodick, D. W. AU - Aurora, S. K. AU - Turkel, C. C. AU - Binder, W. J. PY - 2010 DA - 2010// TI - Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program JO - Headache VL - 50 UR - https://doi.org/10.1111/j.1526-4610.2010.01766.x DO - 10.1111/j.1526-4610.2010.01766.x ID - Blumenfeld2010 ER - TY - JOUR AU - Blumenfeld, A. M. AU - Stark, R. J. AU - Freeman, M. C. AU - Orejudos, A. AU - Manack Adams, A. PY - 2018 DA - 2018// TI - Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study JO - J Headache Pain VL - 19 UR - https://doi.org/10.1186/s10194-018-0840-8 DO - 10.1186/s10194-018-0840-8 ID - Blumenfeld2018 ER - TY - JOUR AU - Santoro, A. AU - Fontana, A. AU - Miscio, A. M. AU - Zarrelli, M. M. AU - Copetti, M. AU - Leone, M. A. PY - 2017 DA - 2017// TI - Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting JO - Neurol Sci VL - 38 UR - https://doi.org/10.1007/s10072-017-3054-y DO - 10.1007/s10072-017-3054-y ID - Santoro2017 ER - TY - JOUR AU - Cernuda-Morollon, E. AU - Ramon, C. AU - Larrosa, D. AU - Alvarez, R. AU - Riesco, N. AU - Pascual, J. PY - 2015 DA - 2015// TI - Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? JO - Cephalalgia VL - 35 UR - https://doi.org/10.1177/0333102414561873 DO - 10.1177/0333102414561873 ID - Cernuda-Morollon2015 ER - TY - JOUR AU - Guerzoni, S. AU - Pellesi, L. AU - Baraldi, C. AU - Cainazzo, M. M. AU - Negro, A. AU - Martelletti, P. PY - 2017 DA - 2017// TI - Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy JO - Front Neurol VL - 8 UR - https://doi.org/10.3389/fneur.2017.00586 DO - 10.3389/fneur.2017.00586 ID - Guerzoni2017 ER - TY - JOUR AU - Negro, A. AU - Curto, M. AU - Lionetto, L. AU - Crialesi, D. AU - Martelletti, P. PY - 2015 DA - 2015// TI - OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study JO - SpringerPlus VL - 4 UR - https://doi.org/10.1186/s40064-015-1636-9 DO - 10.1186/s40064-015-1636-9 ID - Negro2015 ER - TY - JOUR AU - Negro, A. AU - Curto, M. AU - Lionetto, L. AU - Martelletti, P. PY - 2016 DA - 2016// TI - A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience JO - J Headache Pain VL - 17 UR - https://doi.org/10.1186/s10194-016-0591-3 DO - 10.1186/s10194-016-0591-3 ID - Negro2016 ER - TY - JOUR AU - Khalil, M. AU - Zafar, H. W. AU - Quarshie, V. AU - Ahmed, F. PY - 2014 DA - 2014// TI - Prospective analysis of the use of onabotulinumtoxinA (Botox) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K JO - J Headache Pain VL - 15 UR - https://doi.org/10.1186/1129-2377-15-54 DO - 10.1186/1129-2377-15-54 ID - Khalil2014 ER - TY - JOUR AU - Martin, B. C. AU - Pathak, D. S. AU - Sharfman, M. I. AU - Adelman, J. U. AU - Taylor, F. AU - Kwong, W. J. PY - 2000 DA - 2000// TI - Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1) JO - Headache VL - 40 UR - https://doi.org/10.1046/j.1526-4610.2000.00030.x DO - 10.1046/j.1526-4610.2000.00030.x ID - Martin2000 ER - TY - JOUR AU - Cole, J. C. AU - Lin, P. AU - Rupnow, M. F. PY - 2007 DA - 2007// TI - Validation of the migraine-specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment JO - Qual Life Res VL - 16 UR - https://doi.org/10.1007/s11136-007-9217-1 DO - 10.1007/s11136-007-9217-1 ID - Cole2007 ER - TY - JOUR AU - Walters, S. J. AU - Brazier, J. E. PY - 2005 DA - 2005// TI - Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D JO - Qual Life Res VL - 14 UR - https://doi.org/10.1007/s11136-004-7713-0 DO - 10.1007/s11136-004-7713-0 ID - Walters2005 ER - TY - JOUR AU - Pedraza, M. I. AU - Cruz, C. AU - Ruiz, M. AU - Lopez-Mesonero, L. AU - Martinez, E. AU - Lera, M. PY - 2015 DA - 2015// TI - OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm JO - SpringerPlus VL - 4 UR - https://doi.org/10.1186/s40064-015-0957-z DO - 10.1186/s40064-015-0957-z ID - Pedraza2015 ER - TY - JOUR AU - Kollewe, K. AU - Escher, C. M. AU - Wulff, D. U. AU - Fathi, D. AU - Paracka, L. AU - Mohammadi, B. PY - 2016 DA - 2016// TI - Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting JO - J Neural Transm VL - 123 UR - https://doi.org/10.1007/s00702-016-1539-0 DO - 10.1007/s00702-016-1539-0 ID - Kollewe2016 ER - TY - STD TI - Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD (2016) Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. J Headache Pain 17:84 ID - ref36 ER - TY - JOUR AU - Matharu, M. AU - Pascual, J. AU - Nilsson Remahl, I. AU - Straube, A. AU - Lum, A. AU - Davar, G. PY - 2017 DA - 2017// TI - Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe JO - Cephalalgia VL - 37 UR - https://doi.org/10.1177/0333102417724150 DO - 10.1177/0333102417724150 ID - Matharu2017 ER - TY - JOUR AU - Maasumi, K. AU - Thompson, N. R. AU - Kriegler, J. S. AU - Tepper, S. J. PY - 2015 DA - 2015// TI - Effect of onabotulinumtoxinA injection on depression in chronic migraine JO - Headache VL - 55 UR - https://doi.org/10.1111/head.12657 DO - 10.1111/head.12657 ID - Maasumi2015 ER - TY - JOUR AU - McCormack, H. M. AU - Horne, D. J. AU - Sheather, S. PY - 1988 DA - 1988// TI - Clinical applications of visual analogue scales: a critical review JO - Psychol Med VL - 18 UR - https://doi.org/10.1017/S0033291700009934 DO - 10.1017/S0033291700009934 ID - McCormack1988 ER - TY - JOUR AU - Herd, C. P. AU - Tomlinson, C. L. AU - Rick, C. AU - Scotton, W. J. AU - Edwards, J. AU - Ives, N. PY - 2018 DA - 2018// TI - Botulinum toxins for the prevention of migraine in adults JO - Cochrane Database Syst Rev VL - 6 ID - Herd2018 ER -